Drug Trial Radar · NCT05426486
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
May 23, 2022
Primary completion
Dec 30, 2025
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Caigang LiuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open label Phase II-III neoadjuvant study comparing the efficacy and safety of ARX788 combined with pyrotinib maleate versus TCBHP (trastuzumab plus pertuzumab with docetaxel and carboplatin) in patients with HER2-positive breast cancer.
Conditions
- HER2-positive Breast Cancer
Interventions
ARX788Drug
HER2 antibody-drug conjugate
Pyrotinib maleateDrug
EGFR/HER2 dual inhibitor
TrastuzumabDrug
anti-Her2 monoclonal antibody
PertuzumabDrug
anti-HER2 monoclonal antibody
DocetaxelDrug
Cytotoxic chemotherapy
CarboplatinDrug
Cytotoxic chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total pathological complete response rate (tpCR) rateTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.